Thomas Pabst
YOU?
Author Swipe
View article: Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers
Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers Open
T-cell-redirecting bispecific antibodies (bsABs) offer a novel therapeutic approach for relapsed/refractory large B-cell lymphoma (r/r LBCL). However, predictive biomarkers are needed to identify patients most likely to respond. As both bs…
View article: Randomized Phase II Study of Brentuximab‐Vedotin With High‐Dose Chemotherapy in CD30 Positive Lymphoma
Randomized Phase II Study of Brentuximab‐Vedotin With High‐Dose Chemotherapy in CD30 Positive Lymphoma Open
Patients with Hodgkin lymphoma (HL) or peripheral T‐cell lymphoma (PTCL) who relapse after high‐dose chemotherapy (HDCT) have a dismal prognosis. Brentuximab‐vedotin (BV) is a CD30‐targeting antibody‐drug‐conjugate (ADC) used in first‐line…
View article: Clinical Impact of LAG3 Single-Nucleotide Polymorphism in DLBCL Treated with CAR-T Cell Therapy
Clinical Impact of LAG3 Single-Nucleotide Polymorphism in DLBCL Treated with CAR-T Cell Therapy Open
Lymphocyte-activation gene 3 (LAG3) is an immune checkpoint receptor and inhibitory regulator of T-cells. Here, we analyzed the prevalence of LAG3 rs870849 in B-cell lymphoma patients and the treatment outcomes according to the LAG3 geneti…
View article: Observation of PICALM::MLLT10-rearrangement and coincidental EZH2 mutations in a patient with acute myeloid leukemia: A case report and review of the literature
Observation of PICALM::MLLT10-rearrangement and coincidental EZH2 mutations in a patient with acute myeloid leukemia: A case report and review of the literature Open
Acute Myeloid Leukemia (AML) with rearranged PICALM::MLLT10 is a rare and poorly characterized entity. Here, we describe a patient with this rearrangement, and compare this case to the literature. We observed a trend towards young age, mal…
View article: Sex-Associated Differences in Outcomes in Acute Myeloid Leukemia Patients Following Intense Induction Treatment: A Real-World Single Center Analysis
Sex-Associated Differences in Outcomes in Acute Myeloid Leukemia Patients Following Intense Induction Treatment: A Real-World Single Center Analysis Open
Background: Acute myeloid leukemia (AML) is a challenging disease due to its aggressive nature and interindividual variability in treatment response. While sex differences in AML incidence and outcomes have been reported, the impact of sex…
View article: Incidence of Acute Kidney Injury in Autologous Hematopoietic Stem Cell Transplant Recipients According to the Administration of Empirical Amikacin: A Two-Centre Retrospective Cohort Study
Incidence of Acute Kidney Injury in Autologous Hematopoietic Stem Cell Transplant Recipients According to the Administration of Empirical Amikacin: A Two-Centre Retrospective Cohort Study Open
Background: The benefit of adjunctive aminoglycosides in the treatment of patients with febrile neutropenia (FN) is controversial. We investigated the incidence of acute kidney injury (AKI) in patients with FN or suspected infection accord…
View article: Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial Open
View article: CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy
CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy Open
In this retrospective analysis on patients treated with CAR T‐cells at our center, we report on the use of radiotherapy in this setting. Our real‐world cohort of 90 patients with aggressive lymphomas was treated with CARs from 2019 until D…
View article: Clonal Hematopoiesis and Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with AML, Myeloma, and Lymphoma
Clonal Hematopoiesis and Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with AML, Myeloma, and Lymphoma Open
Autologous stem cell transplantation (ASCT) after high-dose chemo-therapy (HDCT) is an option of consolidation therapy in patients with AML, lymphoma, or myeloma. Clonal hematopoiesis (CH) is a premalignant state, associated with an increa…
View article: Serum Immunoglobulin Changes in Multiple Myeloma Patients Treated with CAR T-Cell Therapy
Serum Immunoglobulin Changes in Multiple Myeloma Patients Treated with CAR T-Cell Therapy Open
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment for relapsed or refractory multiple myeloma (RRMM), with high response rates of 80–95%. Serum immunoglobulin changes have been observed throughout conventi…
View article: Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real‐world analysis
Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real‐world analysis Open
View article: Clinical Impact of CTLA-4 Single-Nucleotide Polymorphism in DLBCL Patients Treated with CAR-T Cell Therapy
Clinical Impact of CTLA-4 Single-Nucleotide Polymorphism in DLBCL Patients Treated with CAR-T Cell Therapy Open
FMC63-CAR T cell therapy targeting CD19 protein on malignant B-cells is effective in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), with complete response rates of 43–54%. Common germline variants of the im…
View article: Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis
Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis Open
Relapsed/refractory multiple myeloma (RRMM) patients with dialysis‐dependent renal impairment face limited therapeutic options due to exclusion from clinical trials, a lack of evidence‐based guidelines, and inferior outcomes. Bispecific an…
View article: 327 | LONG‐TERM OUTCOME OF PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA ACHIEVING CR USING BISPECIFIC ANTIBODIES
327 | LONG‐TERM OUTCOME OF PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA ACHIEVING CR USING BISPECIFIC ANTIBODIES Open
View article: 670 | OUTCOME OF SECOND‐LINE AXICABTAGENE CILOLEUCEL IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA PATIENTS: REAL‐WORLD ANALYSIS IN THE DACH AREA (GERMANY, AUSTRIA, SWITZERLAND)
670 | OUTCOME OF SECOND‐LINE AXICABTAGENE CILOLEUCEL IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA PATIENTS: REAL‐WORLD ANALYSIS IN THE DACH AREA (GERMANY, AUSTRIA, SWITZERLAND) Open
View article: Comparability of external and internal control patients for the prospective randomized <scp>HOVON</scp>‐103 trial in older <scp>AML</scp> patients
Comparability of external and internal control patients for the prospective randomized <span>HOVON</span>‐103 trial in older <span>AML</span> patients Open
Summary Real‐world data (RWD) previously contributed to post‐marketing regulatory decision‐making, but are currently also considered as external controls to single‐arm trials. The use of RWD control data may be compromised by methodologica…
View article: A revised prognostic model for patients with acute myeloid leukemia and first relapse
A revised prognostic model for patients with acute myeloid leukemia and first relapse Open
Most patients with acute myeloid leukemia (AML) may obtain remission upon induction chemotherapy, but relapse is frequent and associated with poor survival. Previous prognostic models for outcomes after relapse lacked analysis of comprehen…
View article: Prognostic Value of Post-Transplant MRD Negativity in Standard Versus High- and Ultra-High-Risk Multiple Myeloma Patients
Prognostic Value of Post-Transplant MRD Negativity in Standard Versus High- and Ultra-High-Risk Multiple Myeloma Patients Open
Background: Cytogenetic abnormalities and the persistence of minimal residual disease (MRD) following autologous stem cell transplantation (ASCT) are two established prognostically unfavorable biomarkers in multiple myeloma (MM). Previous …
View article: Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma Open
Patients with large B-cell lymphoma (LBCL) who experience relapsed disease after CD19-directed chimeric antigen receptor (CAR) T-cell (CAR-T) therapy have a poor prognosis. Bispecific antibodies (BsAbs) induce complete remissions in ∼35% o…
View article: Adherence to Multidisciplinary Tumor Board Recommendations in Patients with Multiple Myeloma
Adherence to Multidisciplinary Tumor Board Recommendations in Patients with Multiple Myeloma Open
Background: Patient management following a multidisciplinary tumor board (MTB) recommendation has become standard of care in oncology and aims to ensure optimization and personalization of patient care. To assess the impact of MTB recommen…
View article: Adolescents and young adults with cancer in Switzerland: a large single-centre analysis of key care pathways and outcomes by sex and age
Adolescents and young adults with cancer in Switzerland: a large single-centre analysis of key care pathways and outcomes by sex and age Open
Background Adolescents and young adults with cancer (AYA) represent a distinct patient group with unique challenges. Most studies reporting outcomes use registry data, leaving local care aspects underreported. Aim To understand demographic…
View article: Impact of Venetoclax Treatment Schedule on Hematologic Recovery and Treatment Response in AML Patients Unfit for Intensive Chemotherapy
Impact of Venetoclax Treatment Schedule on Hematologic Recovery and Treatment Response in AML Patients Unfit for Intensive Chemotherapy Open
(1) Background: The combination of venetoclax and hypomethylating agents (HMAs) is a standard first-line regimen for acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. Since venetoclax-HMAs are usually administered unt…
View article: CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents Open
View article: Magrolimab plus azacitidine vs physician’s choice for untreated <i>TP53</i>-mutated acute myeloid leukemia: the ENHANCE-2 study
Magrolimab plus azacitidine vs physician’s choice for untreated <i>TP53</i>-mutated acute myeloid leukemia: the ENHANCE-2 study Open
Patients with TP53-mutated acute myeloid leukemia (AML) have an extremely poor prognosis, necessitating new treatments. The global, randomized, phase 3 ENHANCE-2 trial evaluated the anti-CD47 monoclonal antibody magrolimab plus azacitidine…
View article: Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Open
Fitness assessment in patients with acute myeloid leukemia (AML) is critical to deliver the right therapy to the right patient. Although several scoring systems are available to aid in determining fitness, the absence of validation studies…
View article: Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature
Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature Open
INTRODUCTION: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare disease, with unique diagnostic challenges and often dismal outcome. There are no widely accepted treatment guidelines available. Lymphoma-like regimens with…
View article: Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study Open
Idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM), but direct comparisons are lacking. Leveraging an international multicenter RRMM c…
View article: Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study
Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study Open
Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) after at least 2 prior treatment lines, but real-world data are scarce. In this retrospective, multicen…
View article: Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy Open
Despite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following r…
View article: Low-Frequency PPM1D Gene Mutations Associated with Inferior Treatment Response to CD19 Targeted CAR-T Cell Therapy in Mantle Cell Lymphoma
Low-Frequency PPM1D Gene Mutations Associated with Inferior Treatment Response to CD19 Targeted CAR-T Cell Therapy in Mantle Cell Lymphoma Open
Background/Objectives: Mantle cell lymphoma (MCL) represents a rare B-cell lymphoma subtype with rather high relapse rates. Somatic mutations in the PPM1D gene were shown to be associated with adverse outcomes in patients with diffuse larg…